Deal Sheet

As a consultant, I've worked on 5-10 signed deals a year, with upfronts ranging from $300K to $50M.  Deals I've worked on include big deals from Phase 3 to technologies, JVs, in-licensing and out-licensing.

Strategic Alliances (>$25MM upfront)

• Consulting Client - Big pharma, $50MM upfront, Phase 3, advice on negotiations
• Consulting Client – Big Asian Pharma, $25MM upfront, clinical development, valuation, advice on negotiations
• Consulting Client – Big pharma, $25MM upfront, negotiations & advice (pseudo auction, pre-completion of Phase II)
• Consulting client – Big Pharma: $30MM upfront, broad chemistry collaboration; advice and deal structure
• Tularik -Amgen: $125MM upfront, targets and drug development, led evaluation team, launched collaboration that led to acquisition

• Praecis - Amgen: $100MM upfront,Ph 3 GnRH antagonist, led evaluation team

• Immunomedics - Amgen: $65MM upfront, Ph 2/3 NHL Ab, led evaluation team and member of negotiation team

• Abgenix - Amgen: multi-antigen Ab creation, supervised evaluator and negotiator

• Medarex - Amgen: multi-antigen Ab creation, supervised evaluator and negotiator

• Kinetix acquisition - Amgen: $170MM upfront, kinases and structural biology, led evaluation and diligence

Mid-Size Deals (>$10M upfront)

• Consulting Client- Regional Pharma, negotiations and advice (Phase II)
• Consulting Client – US Biotech, negotiations and advice (Phase II)  
• Consulting Client – Major Pharma, advised negotiator (preclinical)
• Consulting Client - territorial deal:  drafted terms, modeled financials, advised on negotiations

• Vanderbilt - Amgen: preclinical Ab, led negotiation

• Biosite - Amgen:  multiple Abs, supervised evaluator and negotiator

• Incyte - Zeneca:  genomics database, on negotiation team

• Pharmacopeia - Zeneca: combinatorial chemistry, on negotiation team

• U C Irvine - Zeneca:  lead optimization ion channels, led evaluation and negotiations

• U College of London - Zeneca: 
  small molecule lead, led renegotiations

Smaller Deals

• Consulting Client - small biotech, JV, participated in negotiations
• Consulting Client – small biotech, territorial deal (preclinical), participated in negotiations
• Consulting Client – University (clinical), valuation, advice throughout negotiations
• Consulting Client – University (platform), led negotiations
• Consulting Client- Mid-sized pharma, led negotiations (preclinical)
• Consulting Client – Mid-sized pharma, advised negotiations (platform)
• Consulting Client – Global pharma, valuations, advised negotiator (preclinical)
• Consulting Client – Small biotech, valuations, advised negotiator (preclinical)
• Consulting Client – Global pharma, part of negotiations (preclinical)
• Consulting Client  -- Small biotech, led negotiations (preclinical)
• Consulting Client – Small biotech, led negotiations (preclinical)
• Consulting Client – University, led in-licensing negotiations (preclinical)
• Consulting Client – University, led in-licensing negotiations (preclinical)
• Consulting Client- University, led in-licensing negotiations (preclinical)
• Consulting Client- small biotech, led in-licensing negotiations (preclinical)
• Dako - Amgen:  companion diagnostic development, supervised evaluator, led negotiations

• Ventana - Amgen:  companion diagnostic development, supervised evaluator, led negotiations

• Skye Pharma - Amgen:  drug delivery, led evaluation and negotiations

• Many biomarker deals: supervisory roles

• Many IP licenses: negotiator and supervisory roles